Previous 10 | Next 10 |
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that clinical data from the Phase 1/2 open-label study of EDP1503, ...
Evelo Biosciences (NASDAQ: EVLO ) has priced its public offering of 12M common stock at $3.75/share, for expected gross proceeds of ~$45M. More news on: Evelo Biosciences, Inc., Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, today announced the pricing of an underwritten ...
CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, today announced that it intends to offer and...
Evelo Bio Moves Ahead with EDP1815 Mid Stage Trial Evelo Biosciences Inc. ( EVLO ) announced that its lead drug candidate EDP1815 will now be a part of TACTIC-E clinical trial. The trial is designed to assess the safety and efficacy of certain experimental therapies in the preventing and...
The following slide deck was published by Evelo Biosciences, Inc. in conjunction with this Read more ...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
Evelo Biosciences (NASDAQ: EVLO ) is up 25% premarket on the heels of the announcement that EDP1815 will be included in the TACTIC-E clinical trial, evaluating the safety and efficacy of certain experimental therapies to prevent and treat complications of COVID-19. More news ...
—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust— —Experimental therapies with potential to prevent and treat complications of COVID-19— —EDP1815 selected as one of two experimental therapies in the trial—...
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the virtual ...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...